PubChem CID 11616111 UNII G1TI012DLT Formula C9H11ClN2O4S | ChemSpider 9790860 3D model (Jmol) Interactive image Molar mass 278.713 g/mol | |
 | ||
JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.
JNJ-26489112 is also being studied as a treatment for major depressive disorder.
References
JNJ-26489112 Wikipedia(Text) CC BY-SA